financetom
Business
financetom
/
Business
/
NY Governor Hochul Praises Passage of Bills on Addictive Social Media Feeds, Children's Data in Legislature
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NY Governor Hochul Praises Passage of Bills on Addictive Social Media Feeds, Children's Data in Legislature
Jun 10, 2024 4:51 AM

07:29 AM EDT, 06/10/2024 (MT Newswires) -- New York State Governor Kathy Hochul on Friday praised the passage of two bills to ban social media platforms from using "addictive" algorithms for child users and to protect children's personal data.

The Stop Addictive Feeds Exploitation, or SAFE, for Kids Act will require social media companies to restrict addictive feeds for users under 18 years old, Hochul's office said. Meanwhile, the New York Child Data Protection Act will prohibit the collection and usage of children's personal data.

The bills represent a "step forward in our efforts to address the youth mental health crisis and create a safer digital environment for young people," Hochul said.

The NY legislation would also require the establishment of parental consent and age verification methods and impose penalties of up to $5,000 per violation, according to the governor's office.

Price: 492.54, Change: -0.42, Percent Change: -0.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tamarack Valley Energy Declares Monthly Dividend
Tamarack Valley Energy Declares Monthly Dividend
Dec 16, 2024
09:15 AM EST, 12/16/2024 (MT Newswires) -- Tamarack Valley Energy ( TNEYF ) on Monday declared a monthly cash dividend on its common shares of $0.01275 per share, same as the prior month. The dividend will be payable on Jan. 15 to shareholders of record at the close of business on Dec. 30. Shares of the company closed down $0.03...
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- GSK (GSK) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the approval of its experimental drug, Jemperli, in combination with chemotherapy, as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. The company said the...
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Dec 16, 2024
09:20 AM EST, 12/16/2024 (MT Newswires) -- Larimar Therapeutics ( LRMR ) said Monday that initial data from its ongoing long-term study of its experimental therapy nomlabofusp in patients with Friedreich's ataxia leaned toward improved clinical outcomes at day 90. The company said patients treated with daily injections of nomlabofusp saw tissue frataxin levels increase, supporting the drug's potential in...
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- Sinovac Biotech ( SVA ) said Monday that it has begun enrollment in a late-stage study of its investigational bivalent vaccine targeting Hand, Foot, and Mouth Disease, or HFMD, caused by enterovirus 71 and coxsackievirus 16. The company said the trial will evaluate the potential vaccine's efficacy, safety, and immune response in children...
Copyright 2023-2026 - www.financetom.com All Rights Reserved